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Macrophages are one of the immune populations frequently found in colorectal tumors
and high macrophage infiltration has been associated with both better and worst
prognosis. Importantly, according to microenvironment stimuli, macrophages may
adopt different polarization profiles, specifically the pro-inflammatory or M1 and the
anti-inflammatory or M2, which display distinct functions. Therefore, concomitantly
with the number of tumor-associated macrophages (TAMs), their characterization is
fundamental to unravel their relevance in cancer. Here, we profiled macrophages in a
series of 150 colorectal cancer (CRC) cases by immunohistochemistry, using CD68 as
a macrophage lineage marker, CD80 as a marker of pro-inflammatory macrophages,
and CD163 as a marker of anti-inflammatory macrophages. Quantifications were
performed by computer-assisted analysis in the intratumoral region, tumor invasive
front, and matched tumor adjacent normal mucosa (ANM). Macrophages, specifically
the CD163+ ones, were predominantly found at the tumor invasive front, whereas
CD80+ macrophages were almost exclusively located in the ANM, which suggests a
predominant anti-inflammatory polarization of TAMs. Stratification according to tumor
stage revealed that macrophages, specifically the CD163+ ones, are more prevalent
in stage II tumors, whereas CD80+ macrophages are predominant in less invasive T1
tumors. Specifically in stage III tumors, higher CD68, and lower CD80/CD163 ratio
associated with decreased overall survival. Importantly, despite the low infiltration of
CD80+ cells in colorectal tumors, multivariate logistic regression revealed a protective role
of these cells regarding the risk for relapse. Overall, this work supports the involvement of
distinct microenvironments, present at the intra-tumor, invasive front and ANM regions,
on macrophage modulation, and uncovers their prognostic value, further supporting the
relevance of including macrophage profiling in clinical settings.
Keywords: colorectal cancer, tumor immunomodulation, tumor-associated macrophages, human macrophage
surface markers, macrophage polarization, prognostic and tumor relapse
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INTRODUCTION
A variety of non-malignant stromal cells present at the complex
tumormicroenvironment are active players in cancer progression
(1). Specifically in solid tumors, tumor associated macrophages
(TAMs) are one of the most represented populations (2) and
have important roles in the invasive, angiogenic, and metastatic
processes (3, 4).
Macrophages are extremely plastic cells that are able to
respond and adapt to external stimuli (5). Currently, the most
accepted model of macrophage classification describes several
polarization statuses between two extreme populations: the M1-
like or pro-inflammatory, and the M2-like or anti-inflammatory.
In the presence of factors such as lipopolysaccharide (LPS),
interferon (IFN)-γ or tumor necrosis factor (TNF)-α (6),
macrophages adopt a pro-inflammatory phenotype, with high
antigen presenting capacity and production of cytokines such
as interleukin (IL)-6, IL-12, TNF-α, IFN-γ, and reactive oxygen
species (ROS). These cells are known for their bactericidal and
pro-inflammatory functions (7). On the other extreme of the
spectrum are the M2-macrophages, induced by factors such
as IL-4, IL-13, IL-10 or glucocorticoids, which produce anti-
inflammatory cytokines, specifically transforming growth factor
(TGF)-β and IL-10 (8). They are characterized by their scavenger,
angiogenic, and pro-invasive properties (3, 4). As a consequence
of the immunosuppressive tumor microenvironment, namely
due to high IL-10 and TGF-β levels (9, 10), TAMs are
reported to adopt features common to M2-like macrophages.
They generally produce growth factors, chemokines, and matrix
metalloproteinases (MMPs), which act directly on cancer cells
or in other stromal cells, ultimately leading to tumor growth,
invasion, and metastasis (3).
Several clinical and epidemiological studies have described a
strong association between TAMs infiltration, worst prognosis
and shorter survival in melanoma, breast, and ovarian cancer
(11–15). In the specific case of colorectal cancer (CRC), some
studies conclude that higher macrophage infiltration correlates
with more advanced tumor stages (16) and worst prognosis
(17), while others report that TAMs are associated with
improved survival, specifically in the colon (18), and with
reduced liver metastasis (19). Taken together, these findings
suggest lack of agreement on the role of TAMs on CRC
clinical course. Importantly, the majority of these studies
were solely based on CD68, a macrophage lineage marker,
without taking into consideration differences amongst the
distinct pro- or anti- inflammatory subpopulations. Recognizing
the importance of macrophage polarization, some authors
analyzed markers which discriminate between M1 and M2
subpopulations. In this sense, Algars et al. (20) recently
proposed that the type and distribution of TAMs may influence
the carcinogenic process, ultimately affecting survival. In less
advanced tumor stages, macrophage infiltration was associated
with improved disease free survival, whereas, in stage IV CRC,
high number of CLEVER-1/Stabilin-11+ cells, used as an M2-
marker, correlated with shorter disease-free survival (20). A
recent meta-analysis performed in head and neck squamous
cell carcinoma reinforced the need to evaluate macrophage
subsets: CD68 did not present any prognostic association,
contrarily to what was observed for CD163 which correlated
with decreased survival (21). Nevertheless, in both studies, anti-
inflammatory macrophages were not evaluated. Reports using
nitric oxide synthase 2 (NOS2) as a M1 macrophages marker
and CD163 as a M2 macrophage marker, yielded controversial
results (22, 23). Although NOS2 has been frequently used
to identify pro-inflammatory macrophages in mice, many
research groups argued that differences in human nitric oxide
metabolism likely preclude using it as an appropriate marker
to identify M1 macrophages (24–26). Other limitations of
published studies are related to the use of tissue microarrays
(which may not accurately represent the characteristics of
the tumor), the evaluation of hotspots (an approach that
already presents some bias in the analysis) and the use of a
semiquantitative scoring (which results in more subjective and
less sensitive method).
In this study we performed a quantitative evaluation of
the distinct macrophage subpopulations present in CRC, using
CD68, CD80 and CD163 lineage, pro- and anti-inflammatory
surface markers, respectively, in consecutive histological slides.
Quantifications were performed in the intratumoral region (IT),
tumor invasive front (IF), and tumor adjacent normal mucosa
(ANM) of the same patient, to elucidate how the distinct region
microenvironments may modulate macrophages. Histological
profiling was then combined with clinicopathological and follow-
up data, in order to unravel the clinical impact of distinct
macrophage subpopulations within colorectal tumors, and
discriminate which patients may benefit from immunotherapies
targeting macrophages.
MATERIALS AND METHODS
Clinical Samples
One hundred and fifty CRC primary tumors (83 males
and 67 females, median age 70.5 years old, range 22–93
years), containing in the same histological section tumor and
normal mucosa, were retrieved from the files of the Pathology
Department from Centro Hospitalar Universitário São João
(CHUSJ, Porto, Portugal). Samples were collected during primary
tumor surgical resections between 2007 and 2012. Synchronous
tumors were not included.
All clinicopathological evaluations, including stage, grade,
tumor type and lymphocytic infiltrate, were performed by
experienced pathologists from the CHUSJ Pathology Department
and are included in Table 1. The existence of tumor relapses,
the therapeutic scheme and patient overall survival is also
included. In this retrospective cohort, only five patients received
pre-operative chemotherapy, of which three also received pre-
operative radiotherapy. From the initial cohort, clinical data
for survival analyses was obtained for 136 patients. The
study was approved by the CHUSJ Ethics Committee for
Health (References 259 and 260/11), in agreement with the
Helsinki declaration. Informed consent was obtained from all
the participants.
Immunohistochemical Staining
Specimens were fixed in formalin and embedded in paraffin
in accordance with the routine protocol implemented at the
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TABLE 1 | Patients’ clinicopathological information.
Characteristics No. of patients (%)
Age, median (IQR) 70.5 (62.0–79.0)
Gender, M/F 83 (55.3)/67 (44.7)
ANATOMIC TUMOR REGION
Cecum 11 (7.3)
Ascending colon 25 (16.7)
Transverse colon 21 (14.0)
Descending colon 11 (7.3)
Sigmoid 53 (35.3)
Rectum 29 (19.3)
PATHOLOGICAL STAGE, TNM
Tumor
T1 9 (6.0)
T2 25 (16.7)
T3 93 (62.0)
T4 23 (15.3)
Nodes
N0 85 (56.7)
N+ 65 (43.3)
Metastasis
M0 121 (80.7)
M+ 29 (19.3)
CLINICAL STAGE
I 26 (17.4)
II 51 (34.0)
III 44 (29.3)
IV 29 (19.3)
LYMPHOCYTIC INFILTRATION
Absent/mild 92 (61.3)
Moderate/strong 58 (38.7)
ADJUVANT RADIOTHERAPY
No 135 (90)
Yes 14 (9.3)
Unknown 1 (0.7)
ADJUVANT CHEMOTHERAPY
No 81 (54)
Yes 69 (46)
RELAPSE
No 132 (88.0)
Yes 17 (11.3)
Missing 1 (0.7)
SURVIVAL
Alive 76 (50.7)
Death 60 (40.0)
Unknown 14 (9.3)
CAUSE OF DEATH
Cancer-related 29 (19.3)
Other causes 27 (18)
Missing 4 (2.7)
IQR, interquartile range; M, male; F, female; No, number.
Pathology Department from CHUSJ. Sequential 5µm sections,
from the most representative tumor region and selected by a
Pathologist, were stained with antibodies against CD68 (Dako,
PG-M1), CD80 (R&D, MAB140), and CD163 (Novocastra,
MRQ-26). Briefly, tissues were deparaffinized, hydrated and
endogenous peroxidase activity was blocked with 3% methanol
in hydrogen peroxide for 10min. Following antigen retrieval
in a water bath at 98◦C with Tris EDTA, pH9 (CD68, 20min)
or citrate buffer, pH6 (CD80, 20min; CD163, 40min), primary
antibodies were incubated as follows: CD80 overnight (1:50) at
4◦C, CD68 30min (1:100) and CD163 30min (1:100), both at
room temperature. After washing, labeled polymer secondary
antibody (Envision Detection System, Dako) was added to slides
and peroxidase activity was detected using diaminobenzidine
(DAB) –tetrahydrochloride liquid plus substrate Chromogen
System (Dako). The reaction was stopped with distilled
water and sections were counterstained with haematoxylin
and mounted in Richard-Allan Scientific Mounting
Medium (ThermoFisher).
Macrophage Quantification
Following immunohistochemistry, the slides were digitalized
using a NanoZoomer 2.0HT Hamamatsu camera (Meyer
Instruments). For each marker, ten random areas of the ANM,
IT, and IF were photographed (20x magnification). Using
FIJI/IMAGEJ software, the immunoreactive area (IRA) for each
cell surface marker and each region was calculated on the
basis of red, green and blue segmentation, and represented as
a percentage of the immunoreactive area (IRA%). Afterwards,
the mean of the 10 distinct microscopic fields was calculated
for each marker in each region. Importantly, the images
of the three markers were acquired in the same area from
consecutive sections.
Statistical Analysis
Statistical analyses were conducted in STATA version 12.0
(StataCorp, College Station, Texas) or GraphPad Prism Software
v5 (GraphPad-trial version). Departure from normality was
determined using the Shapiro-Wilk test. Descriptive statistics
included count and frequencies for categorical variables and
median with interquartile range for continuous variables.
Comparison of macrophage populations between and within
locations in the tumor region was performed using Friedman’s
test followed by inter-group comparisons with Wilcoxon test.
Comparisons between left and right colon side were performed
with Mann-Whitney U-test while Kruskal-Wallis with Dunns
multiple comparisons correction was applied in the analysis
according to stage and primary tumor invasiveness. Kaplan-
Meier plots with survival curves were compared with Log-rank
test. The strength of associations between continuous variables
was tested using Spearman’s rank correlation. Association
between macrophage populations and location with relapse
followed a multistep statistical procedure: first, empirical
analyses with unconditional logistic regression adjusting for
age and gender, were carried out to uncover the relevant
independent variables to be included in subsequent multivariate
models (p for retention > 0.05); then, multivariate logistic
regression was conducted to assess the independent strength
of association of macrophage’s characteristics in predicting
risk for CRC progression. Lastly, in order to confirm the
strength of association of the results emerging from multivariate
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analysis, bootstrapping analysis was performed using Monte
Carlo simulations (n= 1,000).
RESULTS
CD68+ and CD163+ Cells Are
Predominantly Found Within the Tumor
Invasive Front Whereas CD80+ Cells Are
Mainly Located in the Tumor Adjacent
Normal Mucosa
Given the difficulty in accurately assessing macrophage number
using the classical approach of counting cells under the
microscope, macrophage populations were evaluated by digitally
quantifying the percentage of IRA%, similarly to what was
carried out by other groups (Supplementary Figure 1) (27,
28). Three markers were used to characterize macrophages:
CD68, a macrophage lineage marker broadly used to identify
these immune cells (16, 18, 20), CD80, a co-stimulatory
molecule expressed by pro-inflammatory macrophages (29), and
CD163, a scavenger receptor associated with anti-inflammatory
macrophages (30). Quantifications were performed in three
regions: the ANM, the IT and the IF (Figure 1). Macrophages
are mainly located at the IF of colorectal tumors comparing
with the IT (5.23 vs. 2.59%) (18, 31), and the ANM (2.27%)
(Figure 2A and Table 2). CD163+ cells are also predominantly
found at the IF (1.65%), whereas the ANM exhibits a higher
density of these anti-inflammatory cells than the IT region (1.04
vs. 0.63%) (Figure 2A and Table 2). Notably, CD80 is almost
exclusively located in the ANM (1.31%). In the tumor regions,
CD80 staining is very low and, similarly to the other markers
evaluated, its expression is higher in the IF than in the IT (0.12
vs. 0.04%) (Figure 2A andTable 2). In the three regions analyzed,
Spearman’s rank correlation test revealed a moderate association
between CD68 and CD163 staining (rs >0.5), suggesting that
tumors with higher levels of CD68 also present higher infiltration
of CD163+ cells (Supplementary Table 1).
Since the quantifications for each marker were performed
in consecutive sections of the same area, the percentage
of pro-inflammatory and anti-inflammatory cells among the
overall macrophage population was assessed calculating the ratio
between CD80 and CD68 or CD163 and CD68 expression
(Figure 2B and Table 2). Interestingly, at the ANM, CD80
staining represented almost 75% of the total CD68 staining.
Of note, some of the cases studied had a higher CD80 IRA%
compared with CD68, suggesting that CD80 is not exclusively
expressed by macrophages. Within the IT and IF, the percentage
of cells expressing CD80 relatively to CD68 decreased to ∼2 and
3.45%, respectively. As for CD163, its expression represents about
50% of the total CD68 staining in ANM. Despite the increase
of CD163+ cells at the IF, their percentage relatively to CD68
expression is still lower than what was observed in ANM (38.7%).
Taken together, these observations demonstrate the presence of a
significant number of macrophages at the IF and IT regions that
do not express CD80 or CD163.
The ratio CD80/CD163 was also calculated to evaluate the
proportion between pro- and anti-inflammatory macrophages
(Figure 2C and Table 2). In the ANM, CD80 expression is 1.5
times higher compared to CD163. Conversely, both in IT and
IF, CD163 expression is 10 times higher than CD80. Spearman’s
test revealed a positive association regarding CD80/CD163
ratio between IT and IF (rs = 0.57) (Supplementary Table 1),
suggesting that specimens with lower CD80/CD163 ratio at the
IT region, are also the ones with a lower CD80/CD163 ratio at
the IF.
Adjacent Normal Mucosa and Tumors in
the Right-Sided Colon Exhibit Higher
Macrophage Infiltration
Given the known differences between the right and left-
sided colon, not only in terms of anatomy and genetic
alterations but also considering the microbiota present (32),
macrophage populations in both locations were compared
(Supplementary Table 2). Interestingly, CD68, CD80, and
CD163 infiltration was higher in the ANM of tumors in the
right than in the left-sided colon. Increased infiltration was
also observed for CD68 and CD163 in the IT. Nevertheless,
at the IF, the previously described differences between left
and right-sided colon are lost for the three macrophage
markers analyzed.
FIGURE 1 | Immunostaining of CD68, CD80, and CD163 in the tumor adjacent normal mucosa, intratumoral region and invasive front of a representative colorectal
cancer case, in consecutive paraffin-embedded sections. Specifically, it belongs to a stage IIa colorectal tumor in the ascending colon. Scale bar = 200µm.
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FIGURE 2 | Quantifications of CD68, CD80 and CD163 in the 150 colorectal cancer cases. (A) Percentage of immunoreactive area (IRA%) of CD68, CD80, and
CD163 in the tumor adjacent normal mucosa (ANM), intratumoral region (IT) and invasive front (IF). (B) Percentage of CD80/CD68 and CD163/CD68 ratios in the
ANM, IT, and IF calculated from the IRA%. (C) CD80/CD163 ratio in the ANM, IT and IF calculated from the IRA%. Each dot represents one patient, calculated by
averaging the quantification of 10 areas. Median and inter-quartile range are also included.
TABLE 2 | Comparisons of percentage of immunoreactive area (IRA%) for CD68,
CD80 and CD163, and CD80/CD68, CD163/CD68, and CD80/CD163 ratios in
the adjacent normal mucosa, intratumoral region and invasive front.
Adjacent
normal
mucosa
Intratumoral
region
Invasive front p value*
CD68
(IRA %)
2.27
(1.56–2.83)
2.59
(1.60–3.79)
5.23
(3.05–8.34)
p <0.0001a
CD80
(IRA %)
1.31
(0.73–2.26)
0.04
(0.01–0.17)
0.12
(0.04–0.31)
p < 0.0001b
CD163
(IRA %)
1.04
(0.57–1.57)
0.63
(0.20–1.26)
1.65
(0.96–3.70)
p < 0.0001c
CD80/68
ratio (%)
73.75
(35.64–127.05)
2.06
(0.70–8.22)
3.45
(1.12–7.91)
p < 0.0001d
CD163/68
ratio (%)
51.98
(32.50–84.32)
26.16
(13.47–47.17)
38.69
(22.72–62.87)
p < 0.0001e
CD80/163
ratio
1.47
(0.76–2.82)
0.10
(0.03–0.28)
0.09
(0.04–0.19)
p < 0.0001f
Data presented as median and inter–quartile range.
*Friedman’s test. Group comparisons using the Wilcoxon test.
aANM vs. IT (p = 4.70 × 10−4), ANM vs. IF (p = 3.65 × 10−22), IT vs. IF (p = 4.80
× 10−19).
bANM vs. IT (p = 8.11 × 10−26), ANM vs. IF (p = 2.36 × 10−25), IT vs. IF (p = 2.22
× 10−9).
cANM vs. IT (p = 5.36 × 10−5), ANM vs. IF (p = 1.55 × 10−11), IT vs. IF (p = 5.21
× 10−21).
dANM vs. IT (p = 2.30 × 10−26), ANM vs. IF (p = 3.05 × 10−26), IT vs. IF (p = 0.089).
eANM vs. IT (p = 1.97 × 10−13), ANM vs. IF (p = 1.46 × 10−5), IT vs. IF (p = 7.95
× 10−9).
fANM vs. IT (p = 2.45 × 10−24), ANM vs. IF (p = 2.76 × 10−26), IT vs. IF (p = 0.155).
IRA, immunoreactive area.
Stage II Tumors Have Higher Infiltration of
CD68+ and CD163+ Cells Whereas CD80+
Cells Are More Abundant in T1 Tumors
Macrophage scores were then assessed according to tumor
stage (Figure 3A). For the three markers analyzed, there
were no differences in the ANM among the distinct CRC
stages. Conversely, CD68+ and CD163+ macrophages were
significantly more abundant at both IF and IT regions of stage II
comparing with stage IV tumors. No differences were observed
for CD80.
In a more profound analysis, macrophage populations
were separately analyzed based on the primary tumor
depth of invasion (Figure 3B). Interestingly, CD80+ cells
were more frequent in the IT and IF of the less invasive
T1 tumors. This was not observed in CD68+ or in
CD163+ cells, which appear to predominantly infiltrate
T3 tumors, although no statistical significant differences
were detected.
Higher CD68 Expression in Stage III
Colorectal Tumors Is Associated With
Decreased Overall Survival
In CRC, the data regarding macrophage infiltration and patient
survival is contradictory (17, 18). In order to perform this
analysis, the IRA% for each marker was stratified into two
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FIGURE 3 | Percentage of Immunoreactive area of CD68, CD80, and CD163 in the adjacent normal mucosa (ANM), intratumoral region (IT) and invasive front (IF)
according to (A) tumor stage or (B) primary tumor invasive depth. Results are presented as mean and standard error of the mean (SEM). Stage I = 26 patients; Stage
II = 51 patients; Stage III = 44 patients; Stage IV = 29 patients. T1 = 9 patients; T2 = 25 patients; T3 = 93 patients; T4 = 23 patients. *p < 0.05, Kruskal-Wallis with
Dunns multiple comparisons.
categories according to the median, as low and high-expressing.
When all patients were included in survival analysis, no
differences were observed regardless of the marker or region
analyzed (data not shown). Moreover, analyses conducted in
colon cancer patients, excluding rectummalignancy, also yielded
no relationship of markers and survival (data not shown).
Given that our retrospective cohort includes all tumor stages,
with different prognosis, the association between macrophages
and survival was evaluated considering stages I + II, stage
III, and stage IV separately. Specifically in stage III tumors,
higher infiltration of CD68+ cells in the IT was associated
with decreased overall survival (Figure 4A). This was no
longer observed in the IF (Figure 4B), nor regarding CD80
or CD163 expression (Figures 4C–F). The association between
patients overall survival and the CD80/CD163 ratio was
also assessed. In stage III tumors, although not statistically
significant, there seems to be an association between higher
CD80/CD163 ratio in the IF and improved overall survival
(Figure 4H). This result suggests that, in stage III, a higher
proportion between pro and anti-inflammatory cells, may
represent a survival advantage. It would be interesting to
perform the same analysis in a bigger cohort to validate
these results.
Lower CD80 Infiltration Is Associated With
Increased Relapse
Local recurrence is a frequent concern in CRC treatment (33)
and efforts are being made to discover factors that might
help predict such risk (34). Among the 150 cases of our
series, 17 experienced relapse. No differences were detected in
the percentage of CD68+ or CD163+ macrophage infiltration
between patients with vs. without relapse, in the three regions
analyzed. Conversely, specimens from patients without relapse,
presented a significantly higher CD80 IRA% in both the IT
(p = 0.016) and in the IF (p = 1.16 × 10−7). Univariate
logistic regression revealed an association between higher CD80
staining at the IF and a decreased risk for relapse (Table 3). This
finding was further confirmed on multivariate logistic regression
that included only variables with significant risk and validated
by bootstrap analysis (Supplementary Table 3). Overall, these
results support a protective role of CD80+ cells at the IF of
colorectal tumors for relapse.
Surprisingly, radiotherapy revealed a significant association
with increased risk of relapse in multivariate analyses, further
confirmed through bootstrapping. This may be related, not to the
therapy itself, but to the specific characteristics of the colorectal
tumors candidate for this therapeutic approach.
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FIGURE 4 | Overall survival curves for stage III colorectal cancer patients. Forty-four stage III CRC patients were divided into two groups, low, and high, according to
the median of immunoreactive area percentage for each marker: (A) CD68, (C) CD80, (E) CD163, and (G) CD80/CD163 ratio in the intratumoral region, and (B) CD68
(D) CD80, (F) CD163, and (H) CD80/CD163 ratio in the invasive front. Kaplan-Meier plots and curves were compared through Log-rank test.
DISCUSSION
Innate immune cells present at the tumor microenvironment
may participate in several stages of cancer progression (28, 35,
36). In particular, TAMs play an important role in tumorigenesis
(4) and, although controversy, high levels of macrophage
infiltration have been associated with poor prognosis and
reduced therapy response, in distinct types of tumors.
In CRC, increased infiltration of lymphocytic cells correlates
with improved clinical outcome. Higher infiltration of T
cells (CD3+), cytotoxic T cells (CD8+), and memory T cells
(CD45RO+) has been associated with longer disease-free and/or
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TABLE 3 | Empirical univariate analysis of independent variables,
clinicopathological and macrophage markers, in association with risk for disease
relapse with adjustment for age and gender.
Risk for disease relapse
Variables OR (95 CI) p value
Tumor anatomic region 1.60 (1.04–2.40) 0.032
Clinical stage 0.68 (0.30–1.90) 0.461
Radiotherapy 18.2 (5.30–61.90) <0.0001
Chemotherapy 3.00 (0.94–9.50) 0.062
ANM*
CD68 0.92 (0.55–1.55) 0.757
CD80 0.85 (0.53–1.37) 0.502
CD163 0.91 (0.52–1.61) 0.757
IT*
CD68 1.09 (0.87–1.36) 0.453
CD80 0.02 (0.00–4.40) 0.153
CD163 0.74 (0.40–1.38) 0.346
IF*
CD68 0.93 (0.81–1.08) 0.365
CD80 0.001 (0.00–0.48) 0.030
CD163 0.82 (0.61–1.13) 0.191
OR, odds ratio; 95CI, 95% confidence interval; ANM, adjacent normal mucosa; IT,
intratumoral region; IF, invasive front; *analyzed as continuous variables. Statistical
significant associations are marked in bold.
overall survival (37). Moreover, the Immunoscore, based on
the quantification of lymphocyte populations (CD3/CD8,
CD3/CD45RO, or CD8/CD45RO), demonstrated higher
robustness and prognostic value than the classical UICC’s
TNM classification for stages I-III. In agreement, this immune-
based classification is currently being introduced into clinical
settings (38–40). Despite being the most represented immune
population in solid tumors, macrophages are not included in
this classification, likely due to contradictory results in studies
addressing their clinicopathologic significance in CRC.
In this study, macrophage profiling was assessed by
quantitative evaluation of a macrophage lineage marker (CD68),
a co-stimulatory receptor expressed by pro-inflammatory
macrophages (CD80) and a scavenger receptor characteristic
of their anti-inflammatory counterparts (CD163). The latter
has been previously described in the literature, including
in studies performed in CRC (23, 41–43). However, the
identification of an ideal pro-inflammatory macrophage marker
has been more challenging. Although several reports used
NOS2 (22, 23, 44), it is becoming more evident that this is a
specific marker of mice but not of human pro-inflammatory
macrophages (25, 26). Our preliminary in vitro analysis revealed
that CD80, referred in the literature as specifically expressed
by M1 macrophages (45), and previously used to identify this
specific subpopulation in tumors (46), is a suitable alternative
(Supplementary Figure 2). Nevertheless, none of these markers
is completely specific and it is possible that other immune cell
populations, namely monocytes, dendritic cells, or activated B
cells, are also recognized.
This study demonstrates that macrophage subpopulations
are not uniformly distributed along the tumor, with distinct
preferences for ANM, IT and IT regions. Our results showed
increase CD68 staining in tumors compared to ANM, supporting
the idea that these cells migrate towards the tumor site
by chemotactic signals (47, 48). Although CD80 was highly
expressed by macrophages at the tumor ANM (∼74%), the
majority of macrophages in intratumor regions lack the
expression of this pro-inflammatory marker. This observation
does not corroborate other studies performed in CRC using
NOS2 as a marker, in which ∼60% of the overall tumor
macrophages were considered pro-inflammatory (23), but again
we argue that this might not be an ideal pro-inflammatory
marker of humanmacrophages. In accordance with the literature,
we confirmed that the IF of colorectal tumors was densely
infiltrated by macrophages and that, of these, <40% were
CD163+ cells (23). We further demonstrated that only 3.5% of
the IF macrophages stained positively for CD80. These results
evidence an alteration of the macrophage inflammatory profile
from the ANM to the neoplastic regions, with a major reduction
of the CD80 expression, not counterbalanced by an increase of
the CD163+ cells. Moreover, it also indicates that more than
half of the TAMs are not expressing any of the polarization
markers selected. Additionally, we cannot exclude that some
macrophages might be expressing both M1 and M2 markers
(22). Given the broad spectrum of M2-macrophages (5), these
results highlight the heterogeneity in TAMs within CRC. A
potential marker to include in future analysis is CD206. Work
by Norton and colleagues describing TAMs subsets in CRC
through flow cytometry showed distinct populations expressing
CD163 and/or CD206 (49). More recently, Feng et al. also
evidenced that, within stage II CRC patients which underwent
radical resection, CD206/CD68 ratio can identify those with
high risk of recurrence and poor prognosis and might benefit
from adjuvant chemotherapy (50). In other models, namely
esophageal squamous cell carcinoma, it was shown that there is
a subpopulation of TAMs that does not express CD163 but is
positive for CD204 (51). In fact, macrophage plasticity and ability
to shift between polarization statuses represents a true challenge
for their characterization. In the future, it will be of upmost
importance to characterizemacrophages not recognized by CD80
or CD163 antibodies, by isolating CD68+CD80−CD163− cells
from formalin-fixed paraffin-embedded tissues and performing
extensive gene expression analysis (52), to identify other
subpopulations with putative relevant prognostic value or as
novel targets for therapeutic modulation. As previously described
by our group, one of the key players that might be determining
these differential macrophage polarization within colorectal
cancer is the extracellular matrix. By using decellularized
human CRC and non-neoplastic mucosa, we demonstrated
that, contrarily to what happens in normal tissues, tumor-
ECM polarizes macrophages toward an anti-inflammatory, pro-
invasive phenotype (53).
Interestingly, when macrophage populations were evaluated
according to tumor stage, CD68 and CD163 expressing cells were
more abundant in stage II tumors in comparison to stage IV,
in agreement to findings from Sickert et al. (47). Conversely,
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Bailey et al. reported a higher macrophage infiltration in
stages III and IV, but this study included a small series
of patients (54). Concerning CD80 staining, in our cohort,
no differences were observed among tumor stages. It is
generally hypothesized that during the initial steps of tumor
development, macrophages recruited to the tumor site acquire
pro-inflammatory and anti-tumor activities. Then, as a result
of increased IL-10 and TGF-β levels, their polarization shifts
toward a pro-tumor anti-inflammatory phenotype (45). For
this reason, macrophage populations were separately analyzed
according to the primary tumor invasiveness depth. Noteworthy,
we observed that specifically CD80+ cells were predominant
in T1 tumors, supporting, to some extent, the previously
mentioned hypothesis.
Significant differences between ascending and descending
colon might be partially explained by embryological origin: while
ascending colon derives from the midgut, the descending colon
is originated in the hindgut. Work by Glebov et al. reporting
gene expression analysis of the ascending and descending normal
colon mucosa from the same subject, revealed clear differences
in the expression of genes involved in the control of many
cellular functions, namely cell proliferation, adhesion, death, and
signal transduction. Moreover, by including fetal samples in their
study, they concluded that, although significant differences are
indeed already established in the embryonic colon, additional
alterations in gene expression arise in postnatal development
(55). The gut microbiome has also been a subject of thorough
investigation and it is now known that the amount and type
of bacteria in the ascending and descending colon are distinct
(56). These differences might be reflected in our findings,
since CD68+, CD163+, and CD80+ macrophages were more
prevalent in the tumor ANM on the ascending side of the
colon. The same was observed in the IT region for both CD68
and CD163. Besides macrophages, other immune cells, namely
some T lymphocytes subpopulations have also been reported as
predominant in ascending colorectal tumors (57). Moreover, it
is described that right-sided tumors have an higher mutational
load which may be involved in the increased recruitment of
immune cells (58). Interestingly, the differences disappeared
at the tumor IF, suggesting that, in this specific region, the
tumor can modulate the immune response regardless of the
initial environment. This might be related with the different
chemokines tumor cells release, which are known to have an
impact in immune cell recruitment and differentiation (59). Our
unexpected results suggesting that radiotherapy associates with
increased risk of relapse are probably not related to the direct
effect of ionizing radiation but, more likely, to the endogenous
molecular characteristics of the tumors recommended for
radiotherapy treatment. These results should be exploited in
future studies.
In terms of prognosis, our results indicate that, within stage
III tumors, higher CD68 infiltration in the IT is associated with
decreased overall survival, contrarily to what was reported by
Malesci et al. Using stage III CRC patients, they reported an
association between high CD68 infiltration and increased overall
survival, but only in patients undergoing 5-FU treatment (28).
Our results further revealed an association between higher
CD80/CD163 ratio at the tumor IF and improved survival,
similarly to what was reported in ovarian cancer (60). Recent
work by Yank and colleagues describes an association between
higher CD163+/CD68+ ratio at the IF of colorectal tumors and
poor prognosis, which is not in accordance with our data. It
would be important to clarify if the quantifications of CD68 and
CD163 were performed in exactly the same tumor regions (61).
This work strengthens the need to establish the inflammatory
profile of existing macrophage populations and to perceive their
distribution at the tumor microenvironment for an accurate
prognostic prediction, and possible, therapeutic intervention.
Different strategies targeting macrophages are currently
under development (62), namely inhibition of monocyte
recruitment (63), or of macrophage activation (64). More
recently, the possibility of reprogramming M2 macrophages
toward the M1-type has also been considered (65). In this sense,
recent work by our group described the immunomodulatory
capacity of polyelectrolyte multilayers containing IFN-γ and
of nanoparticles composed of polyglutamic acid, specifically
in reverting the pro-invasive capacity of IL-10-stimulated
macrophages (66, 67). Accordingly, it is plausible to speculate
that CRC patients might benefit from a therapeutic strategy
aiming at reprogramming TAMs profile, which would result in
an increase of M1 macrophages with a concomitant decrease
of M2 subpopulations. The potential of this approach is further
strengthen by the observation that lower infiltration of CD80+
cells strongly associated with increased risk of relapse. In
hepatocellular carcinoma, an increase in M1 macrophages
associated with increased time until recurrence (68), and
a reduced CD163/CD68 ratio was correlated with a worse
outcome (68), which corroborates, at least partially, our results.
Specifically in CRC, a gene-expression based study published
last year shows that tumors lacking M1 macrophages are
associated with poor prognosis (69). Recent work revealed
that CRC cells co-cultured with M1 macrophages exhibited
increased cell death. Conversely, in the presence of naïve,
unstimulated macrophages, cell death remained unchanged or
even decreased, depending on the cell line (28). Nevertheless,
since this the is first report describing the protective role of
CD80+ cells in preventing CRC relapse, further studies should
be performed to validate the current findings. Moreover, given
the described reduced risk of relapse in colorectal tumors
with higher immunoscore, it would be important to explore
possible associations between the infiltration of CD80+ cells and
cytotoxic or memory T cells.
Altogether, this work contributed to increase the knowledge
regarding macrophage profile in CRC and further reinforced the
complexity of macrophage polarization in tumors. Macrophage
intrinsic plasticity and the capacity to adopt intermediate profiles
between the two extreme populations, the M1 and the M2,
require the use of multiple markers and a combination of
strategies to accurately dissect the overall macrophage phenotype
in tumors. The association of lower CD68 infiltration and
higher CD80/CD163 ratio with increased overall survival within
stage III CRC supports the need for further validations and
reinforces the relevance of including such markers in the already
established Immunoscore. Furthermore, the possible protective
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role of CD80+ cells in preventing relapse might also open
new perspectives in the immunotherapy field. Results presented
here further support the need to foster research focusing on
the development of novel therapeutic strategies to reprogram
macrophages toward the pro-inflammatory and tumoricidal
phenotype (70).
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